Insiders CureVac N.V. Deutsche Boerse AG

Equities

Market Closed - Deutsche Boerse AG Other stock markets 20:19:57 17/05/2024 BST			5-day change	1st Jan Change
3.186 ^EUR	+1.14%		+17.13%	-17.03%

05-02	CUREVAC : A missed opportunity
04-26	UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	MT

CUREVAC : A missed opportunity	05-02
CureVac Hires New Chief Business Officer	04-24	MT
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024	04-24	CI
CureVac's Chief Scientific Officer Steps Down	14/07/23	MT
CureVac N.V. Announces Executive Changes	14/07/23	CI
CureVac N.V. Appoints Michael Brosnan to Supervisory Board	20/06/23	CI
Curevac N.V. Approves the Appointment of Alexander Zehnder and Myriam Mendila as Managing Directors	29/03/23	CI
CureVac's New Chief Development Officer Assumes Office	01/02/23	MT
CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer	01/02/23	CI
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®	31/01/23	EQ
CureVac CEO to Depart in March; Sanofi Executive Named Successor	10/01/23	MT
CureVac Chief Executive Franz-Werner Haas to Step Down; Alexander Zehnder Named Successor	09/01/23	MT
CureVac N.V. Announces CEO Changes	09/01/23	CI
CureVac Announces Executive Changes	18/08/22	CI
CureVac N.V. Announces Board Changes	22/06/22	CI
Nykode Therapeutics Names CureVac Exec As New Chief Development Officer	13/06/22	MT
Novartis Exec To Join CureVac As Chief Development Officer	09/06/22	MT
CureVac N.V. Announces Changes of CDO	07/06/22	CI
CureVac Technology Chief Mariola Fotin-Mleczek to Step Down	18/01/22	MT
CureVac Announces Resignation of Mariola Fotin-Mleczek as Chief Technology Officer	17/01/22	CI

No results for this search

CUREVAC : A missed opportunity

May 02, 2024 at 10:42 pm